Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.

Table 3) sub-analyses of baseline clinical and laboratory variables in viral and nonviral populations retrieved overlapping results to the overall population, with the sole exception of AFP <400 ng/mL in nonviral patients being borderline significant (HR 0.69, p = 0.0953).

also in 11,409 other papers